Cassava Sciences, Inc.

Cassava Sciences, Inc. is a clinical stage biotechnology company that develops drugs for neurodegenerative diseases. Founded in 1998 in Austin, Texas, the company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences is dedicated to developing treatments and diagnostics for Alzheimer’s disease and other neurodegenerative diseases.

The company’s lead therapeutic product candidate is simufilam, a small molecule drug, which has completed Phase 2b clinical trials. Simufilam is a novel, orally available therapy designed to restore the function of the brain’s synapses in patients with Alzheimer’s disease. In addition, the company is also developing an investigational diagnostic product candidate called SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer’s disease.

Cassava Sciences’ team is comprised of a group of experienced scientists and business professionals from the biotechnology, pharmaceutical, and venture capital industries. The company has raised more than $100 million in venture capital funding, and is supported by a number of strategic investors, including ARCH Venture Partners, Canaan Partners, and Frazier Healthcare Partners.